Fate Therapeutics Created by Leading Stem Cell Scientists to Pursue New Approaches to Stem Cell Therapies.Biologists, Chemists, Clinicians from Harvard, Stanford, University of Washington, the Scripps Research Institute, and Massachusetts General Hospital Massachusetts General Hospital Health care The major teaching hospital for Harvard Medical School, widely regarded as one of the best health care centers in the world Partner with Top Investor Groups Technology Bypasses Current Debate on Ethical Use of Embryonic Stem Cells by Using Pharmaceutical Medicines to Modulate Stem Cells stem cells, unspecialized human or animal cells that can produce mature specialized body cells and at the same time replicate themselves. Embryonic stem cells are derived from a blastocyst (the blastula typical of placental mammals; see embryo), which is very young inside the Body and via the Use of "Reprogrammed" Adult Stem Cells SEATTLE -- A group of the nation's most respected leaders in stem cell stem cell In living organisms, an undifferentiated cell that can produce other cells that eventually make up specialized tissues and organs. There are two major types of stem cells, embryonic and adult. biology today announced formation of Fate Therapeutics, a new biotechnology company developing drugs to control cell fate. Fate will harness the healing power of adult stem cells by using small molecule drugs to modulate cells in vivo in vivo /in vi·vo/ (ve´vo) [L.] within the living body. in vi·vo adj. Within a living organism. in vivo adv. (in the body) and by reprogramming Reprogramming refers to erasure and remodeling of epigenetic marks, such as DNA methylation, during mammalian development[1]. After fertilization some cells of the newly formed embryo migrate to the germinal ridge and will eventually become the germ cells mature adult cells into stem cells. "Fate's approach is the dawn of a new day in medicine," said Dr. Ben Shapiro, retired Executive Vice President of Worldwide Basic Research, Merck Research Laboratories, and a member of Fate's Science Advisory Board. "Revolutionary advances in stem cell research have shifted the entire debate. We are proving that adult stem cell proliferation and differentiation can be modulated in the human body, and we now have the ability to induce pluripotent stem cells from adult human tissue rather than relying on the use of stem cells derived from embryos." The company expects to have a lead adult stem cell modulating drug, in a cancer-related indication, enter the clinic in 2008. Fate Therapeutics' Revolutionary Platform is Two-Fold The Fate platform focuses on both regenerative and reprogramming medicine. The Fate regenerative medicine platform involves developing drugs that awaken adult stem cells in the body to repair damaged cells and tissues. The Fate reprogramming medicine platform involves developing drugs to reprogram re·pro·gram tr.v. re·pro·grammed or re·pro·gramed, re·pro·gram·ming or re·pro·gram·ing, re·pro·grams To program again. re mature adult cells into stem cells, which when differentiated can become healthy heart, bone, brain or other tissues. Applications of these two approaches include treating the effects of neurological diseases such as Down syndrome Down syndrome, congenital disorder characterized by mild to severe mental retardation, slow physical development, and characteristic physical features. Down syndrome affects about 1 in every 730 live births and occurs in all populations equally. , Alzheimer's and Parkinson's; healing damaged heart tissue after heart attacks; increasing bone and muscle strength in the severely frail; and protecting organs after infection or transplantation. Fate will also tackle devastating dev·as·tate tr.v. dev·as·tat·ed, dev·as·tat·ing, dev·as·tates 1. To lay waste; destroy. 2. To overwhelm; confound; stun: was devastated by the rude remark. cancers, such as pancreatic and colorectal cancer colorectal cancer Malignant tumour of the large intestine (colon) or rectum. Risk factors include age (after age 50), family history of colorectal cancer, chronic inflammatory bowel diseases, benign polyps, physical inactivity, and a diet high in fat. , by developing drugs to prevent the expansion and maturation of cancer stem cells. Fate's Approach Differs Significantly from Others Working with Stem Cells To date, most stem cell companies have focused on cell therapy using harvested cells from cord blood cord blood n. Blood present in the umbilical vessels at the time of delivery. or other tissues. In contrast, Fate's approach focuses exclusively on traditional therapeutics, namely small molecules and protein therapeutics, to direct cell fate. In addition to its novel approach, Fate's work has potential broad application across all degenerative diseases, developmental disorders and cancers, and in enabling the creation of healthy patient-identical cells for transplantation. "We have looked at investing in many stem cell companies, but the science and commercial reality just wasn't there yet," said Robert Nelsen, founding partner of ARCH Venture Partners, whose firm co-founded Fate. "Now is the perfect storm; the right biology breakthroughs; a targeted way to use real drugs; and the leading scientists, entrepreneurs, and investors -- all in the same company to develop breakthrough medicines." Founders' Breakthroughs Are Breathtaking in Scope and Implication Fate's founders include researchers from across the United States and multiple scientific disciplines, including basic biology, biological chemistry and translational medicine translational medicine Molecular medicine The constellation of activities which seek to translate the science of gene discovery, gene transfer, and functional genomics into gene-targeted therapies . As authors of many of the most far-ranging breakthroughs in stem cell science, the team is defining the changes in the field: * Philip Beachy, Ph.D., Stanford University Institute for Stem Cell Biology and Regenerative Medicine and HHMI HHMI Howard Hughes Medical Institute HHMI Hispanic Healthy Marriage Initiative , has pioneered the use of synthetic small molecules and natural products to manipulate activities of developmental and stem cell signaling pathways in vitro in vitro /in vi·tro/ (in ve´tro) [L.] within a glass; observable in a test tube; in an artificial environment. in vi·tro adj. In an artificial environment outside a living organism. and in vivo. * Sheng sheng (Chinese; “sage” or “saint”) In Chinese belief, a mortal who attains extraordinary or supernatural powers by self-cultivation and serves as a model for others. Confucius used the term to refer to exemplary rulers of the past. Ding, Ph.D., Scripps Research Institute, has worked on the identification of small molecules and genes that control cell fate, including cell reprogramming and differentiation. Dr. Ding's work has important implications for the development of small molecule drugs that can potentiate po·ten·ti·ate v. 1. To make potent or powerful. 2. To enhance or increase the effect of a drug. 3. To promote or strengthen a biochemical or physiological action or effect. adult stem cells in vivo, and reprogram differentiated cells to new functions. * Randall Moon, Ph.D., University of Washington, Director, Institute for Stem Cell and Regenerative Medicine, HHMI, and UW Department of Pharmacology, has focused on illuminating the biological pathways that control adult stem cells during the process of regeneration to develop new therapeutic methods to activate regeneration. * David Scadden, M.D., Professor, Harvard University, Co-director and Co-founder, Harvard Stem Cell Institute, Director Massachusetts General Hospital Center for Regenerative Medicine, has broken new ground in understanding how blood forming stem cells and other adult stem cells are maintained in the adult body in specialized niches, and in developing therapies that exploit this biology to modulate adult stem cells in vivo. * Leonard Zon, M.D., Harvard University, Director of the Stem Cell Program, Children's Hospital of Boston and HHMI, is a world expert on the biology of adult blood forming stem cells and methods of enhancing their function for cancer and regenerative medicine applications. Esteemed Scientists to Join Fate's Science Advisory Board In addition to the founding scientists, Fate Therapeutics has garnered the expertise of additional stem cell scientists, research leaders, and drug development luminaries to join its Scientific Advisory Board: * Robert Langer, Sc.D.: Institute Professor of Chemical and Biomedical Engineering Biomedical engineering An interdisciplinary field in which the principles, laws, and techniques of engineering, physics, chemistry, and other physical sciences are applied to facilitate progress in medicine, biology, and other life sciences. , Massachusetts Institute of Technology Massachusetts Institute of Technology, at Cambridge; coeducational; chartered 1861, opened 1865 in Boston, moved 1916. It has long been recognized as an outstanding technological institute and its Sloan School of Management has notable programs in business, * Ram Sasisekharan, Ph.D.: Professor of Biological Engineering & Health Sciences and Technology, Massachusetts Institute of Technology * Ben Shapiro, M.D.: Retired Executive Vice President of Worldwide Basic Research, Merck Research Laboratories "Fate's timing is excellent," said Fate's Executive Vice President Tom St. John. "The science is now mature enough. Clear therapeutic modalities have emerged, and the cloud of political and ethical debate surrounding embryonic stem cells is now a thing of the past. We've got a real opportunity to prove that Fate's adult stem cell therapies are the future of medicine." Before joining Fate, St. John was the Vice President of Therapeutic Development at ICOS Corporation overseeing all of ICOS' development programs. World-Class Investment Team Lined up behind Scientists The unparalleled scientific team is backed by leading venture capital firms Name Location Founding date Managing Partners/Directors Specialty Capital managed 5AM Ventures Menlo Park, CA; Waltham, MA 2002 John Diekman, PhD (managing partner), Scott Rocklage, PhD (managing partner), Andrew Schwab (managing partner) life sciences $200M [1] ARCH Venture Partners, Polaris Venture Partners, Venrock and OVP OVP Originalverpackt (German: original packaging) OVP Over Voltage Protection OVP Ostvorpommern (German number plate area code) OVP Originalverpackung (German) , all with successful track records in building some of the world's leading life sciences companies. The syndicate group has a combined $7 billion under management. Ground-breaking biotechnology companies founded by the firms and their partners include Immunex, IDEC IDEC Instituto Brasileiro de Defesa do Consumidor (Portugese: Brazilian Consumer Protection Agency) IDEC Information Design & End-User Computing IDEC Interior Design Educators Council, Inc. Pharmceuticals, Gilead Sciences, Genetics Institute, Illumina, Centocor, Sepracor, Alnylam Pharmaceuticals, Athena Neurosciences, Aviron, Corixa, deCode Genetics, Geron, Glycofi, Ikaria, Millennium Pharmaceuticals, Momenta Pharmaceuticals, Sirna Therapeutics, Trubion Pharmaceuticals, Vical and XenoPort. Fate Therapeutics was co-founded by Alex Rives Language Rive (plural : rives) is a French word meaning "bank" (of a river). Geography Rives is the name of several places: France Rives is the name of 2 communes in France:
About Fate Therapeutics Fate Therapeutics was founded by the world's leading experts in adult stem cell biology to develop and commercialize therapies to control the destiny of cells. The company's revolutionary platforms are focused on developing medicines that awaken adult stem cells resident within the body to fight disease and regenerate damaged cells and tissue, and on the use of small molecules to reprogram mature adult cells to an embryonic-like state. The company's work has broad application, and offers new hope in the treatment of degenerative diseases, developmental disorders and cancer, and in enabling the creation of patient-identical cells for transplantation. Fate has facilities in Seattle, and soon in California and Massachusetts. For more information, see www.fatetherapeutics.com. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion